X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs TEVA PHARMA (Israel) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
TEVA PHARMA
Dec-13
SUN PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs8422,658-   
Low Rs5722,309-   
Sales per share (Unadj.) Rs131.61,525.2-  
Earnings per share (Unadj.) Rs32.795.3-  
Cash flow per share (Unadj.) Rs38.0218.6-  
Dividends per share (Unadj.) Rs3.5083.41-  
Dividend yield (eoy) %0.53.4 14.7%  
Book value per share (Unadj.) Rs152.71,694.2-  
Shares outstanding (eoy) m2,399.26848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.41.6 330.1%   
Avg P/E ratio x21.626.1 83.0%  
P/CF ratio (eoy) x18.611.4 163.9%  
Price / Book Value ratio x4.61.5 316.0%  
Dividend payout %10.787.5 12.2%   
Avg Mkt Cap Rs m1,696,8772,105,694 80.6%   
No. of employees `00017.544.9 39.0%   
Total wages/salary Rs m49,0230-   
Avg. sales/employee Rs Th18,028.328,777.2 62.6%   
Avg. wages/employee Rs Th2,798.80-   
Avg. net profit/employee Rs Th4,479.51,797.7 249.2%   
INCOME DATA
Net Sales Rs m315,7841,293,392 24.4%  
Other income Rs m6,2320-   
Total revenues Rs m322,0161,293,392 24.9%   
Gross profit Rs m100,893354,196 28.5%  
Depreciation Rs m12,648104,546 12.1%   
Interest Rs m3,99825,404 15.7%   
Profit before tax Rs m90,479224,246 40.3%   
Minority Interest Rs m01,019 0.0%   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m0-147,205 0.0%   
Tax Rs m12,116-2,738 -442.5%   
Profit after tax Rs m78,46280,797 97.1%  
Gross profit margin %31.927.4 116.7%  
Effective tax rate %13.4-1.2 -1,096.8%   
Net profit margin %24.86.2 397.7%  
BALANCE SHEET DATA
Current assets Rs m329,537873,552 37.7%   
Current liabilities Rs m178,870761,812 23.5%   
Net working cap to sales %47.78.6 552.3%  
Current ratio x1.81.1 160.7%  
Inventory Days Days7991 87.0%  
Debtors Days Days8396 86.8%  
Net fixed assets Rs m204,766422,450 48.5%   
Share capital Rs m2,3993,184 75.4%   
"Free" reserves Rs m363,9970-   
Net worth Rs m366,3971,436,714 25.5%   
Long term debt Rs m14,361661,340 2.2%   
Total assets Rs m614,1022,955,816 20.8%  
Interest coverage x23.69.8 240.5%   
Debt to equity ratio x00.5 8.5%  
Sales to assets ratio x0.50.4 117.5%   
Return on assets %13.43.6 373.7%  
Return on equity %21.45.6 380.8%  
Return on capital %24.84.9 503.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m19,6340-   
CASH FLOW
From Operations Rs m70,822206,100 34.4%  
From Investments Rs m-42,216-73,029 57.8%  
From Financial Activity Rs m-22,854-247,231 9.2%  
Net Cashflow Rs m6,107-114,160 -5.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 63.67 Rs / USD

Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare SUN PHARMA With: AUROBINDO PHARMA  VENUS REMEDIES  PLETHICO PHARMA  AJANTA PHARMA  DISHMAN PHARMA  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS